Venarus 1000,1000 mg 60 pcs

Name: Venarus 1000,1000 mg 60 pcs
SKU: 294290
Availability: InStock

€58.48

EAN: 4605077012480 SKU: 294290 Categories: Cardiovascular, Medicine, Vein diseases

Description

Venarus® has angioprotective and venotonic effect.

It reduces the stretching of veins, increases their tone and reduces venous stasis; reduces permeability, capillary fragility and increases their resistance; improves microcirculation and lymph outflow.

Systematic administration reduces clinical manifestations of chronic venous insufficiency of the lower limbs of organic and functional nature.

The optimal dose-effect relation is observed when taking 1000 mg per day.

Indications

Venarus® is indicated for therapy of symptoms of chronic vein diseases (elimination and relief of symptoms).
Therapy of symptoms of venous-lymphatic insufficiency:

cramps of the lower extremities;

feeling of heaviness and tautness in the legs;

pain;

“tired” legs.

Therapy of manifestations of venous-lymphatic insufficiency:

edema of lower limbs

trophic changes of skin and subcutaneous tissue

venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Active ingredient

Purified micronized flavonoid fraction (diosmin, flavonoids in terms of hesperidin)

Composition

1 tablet contains:

acting ingredients:

hesperidin (in terms of 100% substance) 100 mg,

diosmin (in terms of 100% substance) 900 mg;

excipients:

cellulose microcrystalline 124 mg,

sodium carboxymethyl starch (sodium starch glycolate) 54 mg,

gelatin 62 mg,

talk 12 mg,

magnesium stearate 8 mg;

coating aids:

hypromellose (hydroxypropyl methylcellulose 41.4 mg, macrogol 6000 (polyethylene glycol 6000) 6.76 mg, sodium lauryl sulfate 0.2 mg, magnesium stearate 2.48 mg, titanium dioxide 7.88 mg, iron oxide red 0.6 mg, iron oxide yellow 0.68 mg.

How to take, the dosage

Orally.

Recommended dosage for veno-lymphatic insufficiency is 1 tablet per day, preferably in the morning, with a meal. The rasp on the tablet is intended solely for dividing in order to facilitate swallowing.

The duration of treatment may be several months (up to 12 months). If symptoms recur, the course of treatment may be repeated as recommended by the physician.

Recommended dose for acute hemorrhoids – 3 tablets daily (1 tablet in the morning, afternoon and evening) for 4 days, then 2 tablets daily (1 tablet in the morning and evening) for the next 3 days.

Recommended dose for chronic hemorrhoids – 1 tablet daily.

Interaction

Not noted.

Should inform the attending physician about all medications taken.

Special Instructions

Before you start taking Venarus® , it is recommended to consult your doctor.

In case of exacerbation of hemorrhoids, administration of Venarus® does not replace specific treatment of other anal disorders. The duration of treatment should not exceed the periods specified in section “Dosage and administration”. If symptoms persist after the recommended course of therapy, a proctologist should be examined and a further therapy should be selected.

If venous circulatory disturbances are present, the maximal effect of treatment is achieved by combination of therapy with healthy (balanced) lifestyle: it is advisable to avoid long soaking in the sun and long standing on feet and it is also recommended to decrease excessive body weight. Walking and, in some cases, wearing special stockings helps to improve blood circulation.

Influence on ability to drive vehicles and mechanisms: no effect.

Contact your doctor immediately if your condition worsens or there is no improvement during treatment.

Synopsis

Orange-pink film-coated tablets, biconvex, oblong in shape with rounded ends, with a rib.

On cross-section the core is grayish-yellow to brownish-gray.

Features

The main excretion of the drug is through the intestine.

Through the kidneys on average about 14% of the drug taken.

Half-life period is 11 hours.

The drug Venarus® undergoes active metabolism, which is confirmed by the presence of phenolic acids in urine.

Contraindications

Hypersensitivity to the active ingredients or excipients that make up the drug.

It is not recommended that women during breast-feeding.

Side effects

The incidence of adverse reactions is presented as follows: very common (≥1/10 cases), common (≥1/100 and < 1/10 cases), infrequent (≥1/1000 and < 1/100 cases), rare (≥1/10000 and < 1/1000 cases) and very rare (< 1/10000 cases). Unwanted reactions, the incidence of which cannot be estimated from the available data, have the designation “frequency unknown”.

Central nervous system: rare – dizziness, headache, general malaise.

Skin: rarely – rash, itching, urticaria; frequency unknown – isolated edema of the face, lips, eyelids, in exceptional cases angioedema.

If any of the adverse reactions mentioned in the instructions worsen, or if you notice other adverse reactions not specified in the instructions, tell your doctor.

Overdose

No cases of overdose have been described.

In case of overdose of the drug seek medical attention immediately.

Pregnancy use

Pregnancy:

Experiments on animals showed no teratogenic effects. To date, there have been no reports of any side effects when using the drug in pregnant women.

Breast-feeding period:

Because of lack of data regarding excretion of the drug with the breast milk, it is not recommended for women during breast-feeding.

Effects on reproduction:

Reproductive toxicity studies have shown no effect on reproduction in rats of either sex.

Similarities

Detralex, Phlebaven, Venolife Duo, Detravenol, Diosmin+Hesperidin, Troxactiv

Additional information

Weight	0.500 kg
Shelf life	3 years. Do not use after the expiration date stated on the package.
Conditions of storage	At a temperature not exceeding 25 C.
Manufacturer	Alium JSC, Russia
Medication form	pills
Brand	Alium JSC